162 related articles for article (PubMed ID: 38338673)
41. Association Between Arg72Pro Polymorphism in
Liu Z; Xiao Z; Li M; Xiao Y; Wang X; He J; Li Y
Cancer Control; 2021; 28():10732748211004880. PubMed ID: 33759598
[TBL] [Abstract][Full Text] [Related]
42. Association between p53 Arg72Pro polymorphism and thyroid cancer risk: a meta-analysis.
Wu B; Guo D; Guo Y
Tumour Biol; 2014 Jan; 35(1):561-5. PubMed ID: 24037912
[TBL] [Abstract][Full Text] [Related]
43. Meta-analysis shows significant association of the TP53 Arg72Pro with ovarian cancer risk.
Shen SQ; Jiang DK; Liu GY; Chen F; Yu L
Mol Biol Rep; 2012 Apr; 39(4):4683-90. PubMed ID: 21952824
[TBL] [Abstract][Full Text] [Related]
44. TP53 Arg72Pro, mortality after cancer, and all-cause mortality in 105,200 individuals.
Kodal JB; Vedel-Krogh S; Kobylecki CJ; Nordestgaard BG; Bojesen SE
Sci Rep; 2017 Mar; 7(1):336. PubMed ID: 28336930
[TBL] [Abstract][Full Text] [Related]
45. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
[TBL] [Abstract][Full Text] [Related]
46. Arg72Pro polymorphism of p53 may predict poor response to medical treatment in ulcerative colitis.
Vietri MT; Riegler G; Pellino G; Molinari AM; Cioffi M
Ann Ital Chir; 2014; 85(6):513-7. PubMed ID: 25712892
[TBL] [Abstract][Full Text] [Related]
47. TP53 Arg72Pro polymorphism (rs1042522) and risk of endometriosis among Asian and Caucasian populations.
Li J; Chen Y; Mo Z; Li L
Eur J Obstet Gynecol Reprod Biol; 2015 Jun; 189():73-8. PubMed ID: 25889195
[TBL] [Abstract][Full Text] [Related]
48. Increased risk of cutaneous melanoma associated with p53 Arg72Pro polymorphism.
Geng P; Liao Y; Ruan Z; Liang H
PLoS One; 2015; 10(3):e0118112. PubMed ID: 25774791
[TBL] [Abstract][Full Text] [Related]
49. Significant association of TP53 Arg72Pro polymorphism in susceptibility to differentiated thyroid cancer.
Khan MS; Pandith AA; Masoodi SR; Khan SH; Rather TA; Andrabi KI; Mudassar S
Cancer Biomark; 2015; 15(4):459-65. PubMed ID: 25835179
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of the p53 Arg72Pro polymorphism and its association with cancer risk: a HuGE review and meta-analysis.
Khan MH; Khalil A; Rashid H
Genet Res (Camb); 2015 Apr; 97():e7. PubMed ID: 25882871
[TBL] [Abstract][Full Text] [Related]
51. TP53 codon 72 polymorphism and P53 protein expression in colorectal cancer specimens in Isfahan.
Dastjerdi MN
Acta Med Iran; 2011; 49(2):71-7. PubMed ID: 21598212
[TBL] [Abstract][Full Text] [Related]
52. The association between the TP53 Arg72Pro polymorphism and colorectal cancer: An updated meta-analysis based on 32 studies.
Tian X; Dai S; Sun J; Jiang S; Jiang Y
Oncotarget; 2017 Jan; 8(1):1156-1165. PubMed ID: 27901479
[TBL] [Abstract][Full Text] [Related]
53. Clinical significance of TP53 (R72P) and MDM2 (T309G) polymorphisms in breast cancer patients.
Yadav P; Masroor M; Tanwer K; Mir R; Javid J; Ahmad I; Zuberi M; Kaza RC; Jain SK; Khurana N; Ray PC; Saxena A
Clin Transl Oncol; 2016 Jul; 18(7):728-34. PubMed ID: 26553387
[TBL] [Abstract][Full Text] [Related]
54. Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies.
Francisco G; Menezes PR; Eluf-Neto J; Chammas R
Int J Cancer; 2011 Aug; 129(4):920-30. PubMed ID: 20886596
[TBL] [Abstract][Full Text] [Related]
55. Arg72Pro polymorphism of TP53 gene and the risk of skin cancer: a meta-analysis.
Ye J; Li XF; Wang YD; Yuan Y
PLoS One; 2013; 8(11):e79983. PubMed ID: 24260330
[TBL] [Abstract][Full Text] [Related]
56. The p53 codon 72 (Arg72Pro) polymorphism is associated with the degree of insulin resistance in type 2 diabetic subjects: a cross-sectional study.
Bonfigli AR; Sirolla C; Testa R; Cucchi M; Spazzafumo L; Salvioli S; Ceriello A; Olivieri F; Festa R; Procopio AD; Brandoni G; Boemi M; Marra M; Franceschi C
Acta Diabetol; 2013 Jun; 50(3):429-36. PubMed ID: 23269546
[TBL] [Abstract][Full Text] [Related]
57. TP53 Codon 72 Polymorphism and the Risk of Colorectal Cancer in an Azerbaijani Population.
Yagublu V; Bayramov B; Yuce M; Aslanov H
Turk J Gastroenterol; 2022 Jun; 33(6):485-490. PubMed ID: 35786616
[TBL] [Abstract][Full Text] [Related]
58. Association between
Dedousi D; Mavrogianni D; Papamentzelopoulou M; Stavros S; Raouasnte R; Loutradis D; Drakakis P
Horm Mol Biol Clin Investig; 2022 Dec; 43(4):421-426. PubMed ID: 35776848
[TBL] [Abstract][Full Text] [Related]
59. TP53 codon 72 polymorphism and type 2 diabetes: a case-control study in South Indian population.
Punja HK; Nanjappa DP; Babu N; Kalladka K; Shanti Priya Dias B; Chakraborty G; Rao SM; Chakraborty A
Mol Biol Rep; 2021 Jun; 48(6):5093-5097. PubMed ID: 34181170
[TBL] [Abstract][Full Text] [Related]
60. Ewing Sarcoma: influence of TP53 Arg72Pro and MDM2 T309G SNPs.
Thurow HS; Hartwig FP; Alho CS; Silva DS; Roesler R; Abujamra AL; de Farias CB; Brunetto AL; Horta BL; Dellagostin OA; Collares T; Seixas FK
Mol Biol Rep; 2013 Aug; 40(8):4929-34. PubMed ID: 23661019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
